Epstein Secrets

32.6% -7.8% $3.7125bn FIR (sTRPR) 11.125% 6/29/18 4.85 93.85 5.00 5.87 11.9% 3.2% 1 - Buy $ 7.50 54.6% 33.6% 1.2% 51.925bn Source: Bloomberg, sANIL. Up/down return vs undenying stock prke .1- 25% o sumes preferred a held to maturity From Aug 2: Risk Parity Risks in US Fixed Income c' id

TEVA's positioning In generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks In Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the le

n oil markets will drag down bonds of drillers and producers, taking the broader Junk Index with them, as defaults and bankruptcies pile up. Source. Bloomberg 8/4/2016 I his mer.sage. std any attaemems, is for the otended reopient(s)only, may contao informatuo that is gelvlieged.ccethdenbal and/or PlOPflet

TEVA's positioning in generic pharma where scale and product diversity are increasingly important. TWA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAM reaffirming BUY after rontier reported its first post-Verizon assets merger results. FTR's ea nings miss was due to a decline in the lega

.6% 32.6% -7.8% $3.7125bn FTR (FTRPR) 11.125% 6/29/18 4.85 93.85 5.00 5.87 11.9% 3.2% 1 - Buy 7.50 54.6% 33.6% 1.2% $1.925bn Source: Bloomberg, BAML. Up/down return vs underlying stock price +/- 25% assum=s preferred is held to maturity =/u> 8 EFTA_R1_01555609 EFTA02454078 Today's

EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l

125% 6/29/18 4.85 93.85 5.00 5 EFTA_R1_01556246 EFTA02454472 5.87 11.9% 3.2% 1 - Buy $&nb=p; 7.50 54.6% 33.6% 1.2% $1.925bn Source: Bloomberg, BAML. Up/down return vs underlying stock price &=43;/- 25% assumes preferred is held to maturity From Aug 2: R=sk Parity Risks in US Fixed Income

ositioning in generic=pharma where scale and product diversity are increasingly important. TEVA =emains one of our top picks in Spec Pharma.<=span> Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a=decline in the l

TRPR) 11.125% 6/29/18 4.85 93.85 5.00 9 EFTA_R1_01557879 EFTA02455326 5.87 11.9% 3.2% 1 - Buy 7.50 54.6% 33.6% 1.2% $1.925bn Source: Bloomberg, BAML. Up/down return vs underlying stock price +/- 25% assum=s preferred is held to maturity =/u> From Aug 2: Risk Parity Risks in US Fixed I

EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l

urity and stock is down 25%: -7.8% 0Di-eligible: No Amount outstanding: $3.7125 bn Assumes convert held to maturity; all coupons included Source: Bloomberg Amanda Ens Director Bank of America Merrill Lynch Merrill Lynch, Pierce, Fenner & Smith Incorporated One B ant Park 5th Floor, New York, NY 1003

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FIR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l

.6% 32.6% -7.8% $3.7125bn FTR (FTRPR) 11.125% 6/29/18 4.85 93.85 5.00 5.87 11.9% 3.2% 1 - Buy 7.50 54.6% 33.6% 1.2% $1.925bn Source: Bloomberg, BAML. Up/down return vs underlying stock price +/- 25% assumes preferred is held to maturity 13 EFTA_R1_01556640 EFTA02454711 From Aug 2: Risk

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l

RPR) 11.125% 6/29/18 12 EFTA_R1_01555900 EFTA02454272 4.85 93.85 5.00 5.87 11.9% 3.2% 1 - Buy 7.50 54.6% 33.6% 1.2% $1.925bn Source: Bloomberg, BAML. Up/down return vs underlying stock price +/- 25% assumes preferred is held to maturity From Aug 2: Risk Parity Risks in US Fixed Income Tod

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l

RPR) 11.125% 6/29/18 4.85 93.85 5.00 5.87 11.9% 3.2% 12 EFTA_R1_01556380 EFTA02454571 1 - Buy 7.50 54.6% 33.6% 1.2% $1.925bn Source: Bloomberg, BAML. Up/down return vs underlying stock price +/- 25% assum=s preferred is held to maturity ./u> =C2 =C2 Today's simultaneous weakness i= the

EVA's positioning in generic pharma where scale and pro=uct diversity are increasingly important. TEVA remains one of our top pick= in Spec Pharma. Frontier Comm (FTR) - BAM= reaffirming BUY after Frontier reported its first post-Verizon assets merger results. =TR's earnings miss was due to a decline in the l

RPR) 11.125% 6/29/18 13 EFTA_R1_00107692 EFTA01785511 4.85 93.85 5.00 5.87 11.9% 3.2% 1 - Buy 7.50 54.6% 33.6% 1.2% $1.925bn Source: Bloomberg, BAML. Up/down return vs underlying stock price +/- 25% assumes preferred is held to maturity From Aug 2: Risk Parity Risks in US Fixed Income Tod

EVA's positioning in generic pharma where scale and product diversity are increasingly important. TEVA remains one of our top picks in Spec Pharma. Frontier Comm (FTR) - BAML reaffirming BUY after Frontier reported its first post-Verizon assets merger results. FTR's earnings miss was due to a decline in the l